These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study. Wei J; Choi HK; Neogi T; Dalbeth N; Terkeltaub R; Stamp LK; Lyu H; McCormick N; Niu J; Zeng C; Lei G; Zhang Y Ann Intern Med; 2022 Apr; 175(4):461-470. PubMed ID: 35073156 [TBL] [Abstract][Full Text] [Related]
6. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. Muanda FT; Weir MA; Bathini L; Blake PG; Chauvin K; Dixon SN; McArthur E; Sontrop JM; Moist L; Garg AX JAMA; 2019 Nov; 322(20):1987-1995. PubMed ID: 31705755 [TBL] [Abstract][Full Text] [Related]
7. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX Clin J Am Soc Nephrol; 2020 Dec; 15(12):1728-1739. PubMed ID: 33239410 [TBL] [Abstract][Full Text] [Related]
8. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. Yokose C; Lu N; Xie H; Li L; Zheng Y; McCormick N; Rai SK; Aviña-Zubieta JA; Choi HK CMAJ; 2019 Sep; 191(39):E1070-E1077. PubMed ID: 31570545 [TBL] [Abstract][Full Text] [Related]
9. Hyperuricaemia, gout and allopurinol in the CKD Queensland registry. Jeyaruban A; Hoy W; Cameron A; Healy H; Wang Z; Zhang J; Mallett A J Nephrol; 2021 Jun; 34(3):753-762. PubMed ID: 33439469 [TBL] [Abstract][Full Text] [Related]
10. High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol. Abdullah SS; Rostamzadeh N; Muanda FT; McArthur E; Weir MA; Sontrop JM; Kim RB; Kamran S; Garg AX Can J Kidney Health Dis; 2024; 11():20543581231221891. PubMed ID: 38186562 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of allopurinol in chronic kidney disease. Thurston MM; Phillips BB; Bourg CA Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601 [TBL] [Abstract][Full Text] [Related]
12. Effects of Allopurinol on the Progression of Chronic Kidney Disease. Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811 [TBL] [Abstract][Full Text] [Related]
13. Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. Kielstein JT; Heisterkamp M; Jing J; Nadal J; Schmid M; Kronenberg F; Busch M; Sommerer C; Lorenzen JM; Eckardt KU; Köttgen A; Clin Kidney J; 2021 Jan; 14(1):277-283. PubMed ID: 33564429 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384 [TBL] [Abstract][Full Text] [Related]
15. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Lee HY; Ariyasinghe JT; Thirumoorthy T Singapore Med J; 2008 May; 49(5):384-7. PubMed ID: 18465047 [TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . Yang AY Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714 [TBL] [Abstract][Full Text] [Related]
17. Examining the use of allopurinol: Perspectives from recent drug injury relief applications. Huang CH; Chu MP; Chen WW J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):371-377. PubMed ID: 29941331 [TBL] [Abstract][Full Text] [Related]
18. Higher dose antiviral therapy for herpes infections is associated with a risk of serious adverse events in older adults with chronic kidney disease. Olar P; Garg AX; Weir MA; Ahmadi F; McArthur E; Lam NN; Sontrop JM; Muanda FT Pharmacol Res Perspect; 2024 Dec; 12(6):e70028. PubMed ID: 39428714 [TBL] [Abstract][Full Text] [Related]
19. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. Yang N; Cao B J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976 [TBL] [Abstract][Full Text] [Related]
20. Allopurinol-Induced Stevens-Johnson Syndrome. Gupta SS; Sabharwal N; Patti R; Kupfer Y Am J Med Sci; 2019 Apr; 357(4):348-351. PubMed ID: 30638600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]